statement: Use of leukotriene inhibitors is not contraindicated for patients with EGPA with active asthma and/or sinonasal disease. Leukotriene inhibitors carry therapeutic indications for asthma and allergic rhinitis. As no clear causal association with EGPA has been demonstrated, a leukotriene inhibitor can be added to help manage asthma and sinonasal disease. However, leukotriene inhibitors are one of many options and are not the only choice in this setting. Leukotriene inhibitors should not